These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 9329528)

  • 1. Generalisation from phase III clinical trials: survival, quality of life, and health economics.
    Fayers PM; Hand DJ
    Lancet; 1997 Oct; 350(9083):1025-7. PubMed ID: 9329528
    [No Abstract]   [Full Text] [Related]  

  • 2. The costs of conducting clinical research.
    Emanuel EJ; Schnipper LE; Kamin DY; Levinson J; Lichter AS
    J Clin Oncol; 2003 Nov; 21(22):4145-50. PubMed ID: 14559889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors to consider when designing phase III clinical trials involving economic evaluations.
    van Enckevort PJ; TenVergert EM; Kingma J; Koëter GH; Rutten FF
    Percept Mot Skills; 1999 Dec; 89(3 Pt 2):1059-72. PubMed ID: 10710753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reliable evidence of safety and efficacy of elderly patients in randomized clinical trials still needed.
    Crean SM; Reynolds MW; Dematto CA
    J Clin Oncol; 2007 Sep; 25(25):4027-8; author reply 4028. PubMed ID: 17761994
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical trials and tribulations. Spiraling costs threaten gridlock.
    Malakoff D
    Science; 2008 Oct; 322(5899):210-3. PubMed ID: 18845742
    [No Abstract]   [Full Text] [Related]  

  • 6. Granulocyte-macrophage colony-stimulating factor as adjunct therapy in relapsed lymphoid malignancy: implications for economic analyses of phase III clinical trials.
    Bennett CL; George SL; Vose JM; Nemunaitis JJ; Armitage JL; Armitage JO; Gorin NC; Gulati SC
    Stem Cells; 1995 Jul; 13(4):414-20. PubMed ID: 7549900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quality of life and clinical trials in HIV infection.
    Barker S; Tindall B; Carballo M
    Lancet; 1990 Apr; 335(8696):1045. PubMed ID: 1970103
    [No Abstract]   [Full Text] [Related]  

  • 8. Health Economics Unit achievements.
    Crott R; Neymark N
    Eur J Cancer; 2002 Mar; 38 Suppl 4():S147-50. PubMed ID: 11858982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of rituximab as maintenance therapy in patients with follicular non-Hodgkin lymphoma after responding to first-line rituximab plus chemotherapy.
    Hornberger J; Chien R; Friedmann M; Han L; Shewade A; Satram-Hoang S; Reyes C
    Leuk Lymphoma; 2012 Dec; 53(12):2371-7. PubMed ID: 22591119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic analysis in phase III clinical cancer trials.
    Bennett CL; Armitage JL; Buchner D; Gulati S
    Cancer Invest; 1994; 12(3):336-42. PubMed ID: 8187012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of a US National Institutes of Health programme of clinical trials on public health and costs.
    Johnston SC; Rootenberg JD; Katrak S; Smith WS; Elkins JS
    Lancet; 2006 Apr; 367(9519):1319-27. PubMed ID: 16631910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The influence of industry sponsorship on the reporting of subgroup analyses within phase III randomised controlled trials in gastrointestinal oncology.
    Barton S; Peckitt C; Sclafani F; Cunningham D; Chau I
    Eur J Cancer; 2015 Dec; 51(18):2732-9. PubMed ID: 26608121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic analysis during phase III clinical trials: who, what, when, where, and why?
    Bennett CL; Westerman IL
    Oncology (Williston Park); 1995 Nov; 9(11 Suppl):169-75. PubMed ID: 8608049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Challenges in the design and conduct of phase III brain tumor therapy trials.
    Perry JR; DeAngelis LM; Schold SC; Burger PC; Brem H; Brown MT; Curran WJ; Scott CB; Prados MD; Kaplan R; Cairncross JG
    Neurology; 1997 Oct; 49(4):912-7. PubMed ID: 9339667
    [No Abstract]   [Full Text] [Related]  

  • 15. 'Health Economics' and the evolution of economic evaluation of health technologies.
    Hutton J
    Health Econ; 2012 Jan; 21(1):13-8. PubMed ID: 22147623
    [No Abstract]   [Full Text] [Related]  

  • 16. Impact of therapeutic research on informed consent and the ethics of clinical trials: a medical oncology perspective.
    Daugherty CK
    J Clin Oncol; 1999 May; 17(5):1601-17. PubMed ID: 10334550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use and abuse of placebo in phase III trials.
    García-Alonso F; Guallar E; Bakke OM; Carné X
    Eur J Clin Pharmacol; 1998 Apr; 54(2):101-5. PubMed ID: 9626912
    [No Abstract]   [Full Text] [Related]  

  • 18. Economic analysis and complex randomized controlled trials.
    Delaney B
    Fam Pract; 2007 Sep; 24(4):293-4. PubMed ID: 17728291
    [No Abstract]   [Full Text] [Related]  

  • 19. Unnecessary holes in the head.
    Gillett GR
    IRB; 2001; 23(6):1-6. PubMed ID: 12737174
    [No Abstract]   [Full Text] [Related]  

  • 20. Evaluation of the cost-effectiveness of entecavir versus lamivudine in hepatitis BeAg-positive chronic hepatitis B patients.
    Yuan Y; Iloeje UH; Hay J; Saab S
    J Manag Care Pharm; 2008; 14(1):21-33. PubMed ID: 18240879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.